SS Innovations International (NASDAQ: SSII) showcased its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console at two international medical conferences in October 2026, demonstrating the feasibility of remote robotic surgery across thousands of miles. The company announced the demonstrations on November 2, 2026, according to a release distributed via NEWMEDIAWIRE. The events underscore a growing effort to use robotics to deliver specialized surgical expertise to patients far from major medical centers.
At the 40th European Association for Cardio-Thoracic Surgery annual meeting in Barcelona, SS Innovations Chairman and CEO Dr. Sudhir Srivastava performed a robotic-assisted atrial septal defect procedure on a patient located approximately 7,500 miles away in Bengaluru, India. The operation relied on the SSi Mantra system and the SSi MantrAsana console, which allow a surgeon to control robotic instruments remotely. The demonstration was part of a broader push to show that long-distance telesurgery can be performed with current technology.
In addition to the cardiac procedure, four other robotic telesurgeries were performed or broadcast during the inaugural Society of Robotic Surgery India conference, covering urological, colorectal, pediatric, and gynecological procedures. These demonstrations illustrate the versatility of the SSi Mantra platform across multiple surgical specialties. The company said that, as of October 23, 2026, 205 telesurgeries had been performed using the SSi Mantra system, including cardiac procedures. The cumulative number suggests that remote robotic surgery is moving from experimental trials toward broader clinical use, although the release did not specify the locations or outcomes of those cases.
The implications of these demonstrations are significant for health systems seeking to address shortages of specialist surgeons in remote or underserved areas. Remote robotic surgery could allow experts to operate on patients who would otherwise need to travel long distances or forego treatment. However, widespread adoption depends on several factors, including clinical validation, reliable connectivity, and regulatory requirements. The release did not provide data on complication rates or long-term outcomes, leaving questions about the safety and efficacy of telesurgery in routine practice.
For SS Innovations, the path to the U.S. market remains a key milestone. The company is pursuing U.S. Food and Drug Administration clearance for the SSi Mantra, with completion of the 510(k) review targeted for the first quarter of 2027. The timeline remains subject to the FDA’s review. FDA clearance would allow the company to market the system in the United States, potentially expanding its commercial reach and validating its technology for American surgeons. Additional details about the company and its platform are available through its SS Innovations (NASDAQ: SSII) profile, and the full announcement can be read at https://ibn.fm/EZFDT.
Investors and clinicians will be watching whether SS Innovations can translate these demonstrations into regulatory approval and clinical adoption. The company’s forward-looking statements are subject to risks and uncertainties, and the release notes that actual results may differ materially. For ongoing updates, the company directs readers to its newsroom at https://ibn.fm/SSII.
